文献速递中毒与环境急症儿科与产科急症

处方药监测计划与青少年及年轻成人苯二氮䓬类处方配发及过量的关联

Association of prescription drug monitoring programs with benzodiazepine prescription dispensation and overdose in adolescents and young adults.
PubMed 文献 · Clin Toxicol (Phila) · 2023-03-15
一句话结论处方药监测计划伴强制提供者审查与青少年及年轻成人苯二氮䓬类处方配发年降6.8%和12.5%相关,但与苯二氮䓬类过量无关。

该州级回顾性队列研究利用美国商业健康保险数据,评估2008年1月1日至2019年12月31日期间处方药监测计划伴强制提供者审查的实施与13-18岁青少年及19-25岁年轻成人苯二氮䓬类处方配发和苯二氮䓬类相关过量的关联。结果显示,实施该计划与青少年苯二氮䓬类处方配发每年减少6.8%(95%CI 1.6-11.8)、年轻成人每年减少12.5%(95%CI 9.3-15.5)相关;但两个年龄组的苯二氮䓬类过量均无减少(青少年每年变化-15.4%[95%CI -21.5至3.0],年轻成人-8.0%[95%CI -18.0至3.2])。作者认为处方配发大幅减少令人鼓舞,但未发现与过量减少的关联,这些发现有助于为制定进一步政策提供信息。

要点

  • 处方药监测计划伴强制提供者审查与青少年苯二氮䓬类处方配发每年减少6.8%(95%CI 1.6-11.8)相关。
  • 该计划与年轻成人苯二氮䓬类处方配发每年减少12.5%(95%CI 9.3-15.5)相关。
  • 两个年龄组的苯二氮䓬类过量均无减少:青少年每年变化-15.4%(95%CI -21.5至3.0),年轻成人-8.0%(95%CI -18.0至3.2)。
  • 队列中74,539名(1.8%)青少年和246,760名(4.0%)年轻成人至少配发过一次苯二氮䓬类处方。
  • 苯二氮䓬类过量发生在1,569名(0.04%)青少年和3,202名(0.05%)年轻成人中。

适用人群与场景

  • 13-18岁青少年和19-25岁年轻成人,数据来自美国一家商业健康保险公司,研究期间为2008年1月1日至2019年12月31日。

研究设计与关键结果

  • 州级回顾性队列研究,纳入13-18岁青少年和19-25岁年轻成人,评估处方药监测计划伴强制提供者审查的实施与苯二氮䓬类处方配发及苯二氮䓬类相关过量的关联。
  • 74,539名(1.8%)青少年和246,760名(4.0%)年轻成人至少配发过一次苯二氮䓬类处方。
  • 苯二氮䓬类过量发生在1,569名(0.04%)青少年和3,202名(0.05%)年轻成人中。
  • 实施处方药监测计划伴强制提供者审查与青少年苯二氮䓬类处方配发每年减少6.8%(95%CI 1.6-11.8)相关。
  • 实施该计划与年轻成人苯二氮䓬类处方配发每年减少12.5%(95%CI 9.3-15.5)相关。
  • 两个年龄组的苯二氮䓬类过量均无减少:青少年每年变化-15.4%(95%CI -21.5至3.0),年轻成人-8.0%(95%CI -18.0至3.2)。

证据类型、等级与局限

  • 证据类型:州级回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,处方药监测计划伴强制提供者审查与苯二氮䓬类处方配发大幅减少相关,但未发现与苯二氮䓬类相关过量减少的关联。
  • 作者认为,这些发现有助于为制定进一步政策以应对该人群苯二氮䓬类误用和过量率上升提供信息。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Prescription drug monitoring programs are state-run databases designed to support safe prescribing of controlled substances and reduce prescription drug misuse. We analyzed healthcare claims data to determine the association between prescription drug monitoring programs with mandated provider review and adolescent and young adult benzodiazepine prescription dispensing and overdose.

METHODS: We performed a state-level retrospective cohort study to evaluate the association between implementation of prescription drug monitoring programs with mandated provider review and benzodiazepine prescription dispensing and benzodiazepine-related overdoses among adolescents (13-18 years) and young adults (19-25 years) between 1 January 2008 and 31 December 2019. Data were obtained from a United States commercial health insurance company.

RESULTS: There were 74,539 (1.8%) adolescents and 246,760 (4.0%) young adults with at least one benzodiazepine prescription dispensed. Benzodiazepine overdoses occurred among 1,569 (0.04%) and 3,202 (0.05%) adolescents and young adults, respectively. Implementation of a prescription drug monitoring program with mandated provider review was associated with a 6.8% (95% CI, 1.6-11.8) yearly reduction in benzodiazepine prescription dispensing among adolescents and a 12.5% (95% CI, 9.3-15.5) yearly reduction among young adults. There was no decrease in benzodiazepine overdoses in either age group (-15.4% [95% CI, -21.5 to 3.0] and -8.0% [95% CI, -18.0 to 3.2] yearly change in adolescents and young adults, respectively).

DISCUSSION: Consistent with prior work, our study did not find an association between prescription drug monitoring program implementation and reduction in benzodiazepine-related overdoses among adolescents and young adults. However, the substantial reduction in benzodiazepine prescription dispensing is encouraging.

CONCLUSION: Prescription drug monitoring programs were associated with decreases in benzodiazepine prescription dispensing, but not benzodiazepine-related overdoses in this cohort of adolescents and young adults. These findings serve to inform development of further policies to address rising rates of benzodiazepine misuse and overdose in this patient population.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Toce MS, Michelson KA, Hudgins JD, et al. Association of prescription drug monitoring programs with benzodiazepine prescription dispensation and overdose in adolescents and young adults. Clin Toxicol (Phila). 2023. PMID: 36919488. doi:10.1080/15563650.2023.2181092

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。